TIDMOBD
Oxford BioDynamics PLC
08 November 2023
Oxford BioDynamics Plc
Oxford BioDynamics strengthens commercial leadership with new
SVP of Business and Corporate Development
-- Appointment of industry veteran Dr Steven Arrivo as SVP business and corporate development.
-- Dr Arrivo to focus on marketing, partnering and sales of the
recently launched EpiSwitch Prostate Screening (PSE) test.
Oxford, UK - 8 November, 2023 - Oxford BioDynamics, Plc (AIM:
OBD, the Company), a biotechnology company developing precision
medicine tests based on the EpiSwitch(R) 3D genomics platform has
appointed Dr Steven Arrivo as Senior Vice President of Business and
Corporate Development. Dr Arrivo brings over 20 years of science
and industry experience along with an established track record in
business and corporate development within personalized medicine
across big pharma, biotech and molecular diagnostics companies.
Dr Arrivo joins Oxford BioDynamics from CellCarta Biosciences
(formerly Caprion) where he spent five years in Business
Development, as Senior Director and Vice President. Prior to that
he was at Biodesix and Ventana Medical Systems. Before then, he
spent four years at Pfizer in various R&D roles and he began
his career at Merck & Co., Inc. as a Senior Project Scientist
following several academic research positions. Dr Arrivo holds a
Bachelor's degree in Chemistry from the University of Eastern
Illinois, and a Master's degree in Synthetic Organic and Inorganic
Chemistry and Ph.D. in Physical Chemistry from Northwestern
University. He completed Postdoctoral studies in Physical Chemistry
at Columbia University.
At OBD, Dr Arrivo's role will be to implement effective
marketing and sales strategies for the newly launched EpiSwitch(R)
PSE prostate cancer detection test. His specific focus will be to
grow sales in the US market, where he has considerable experience
of launching products.
Dr Jon Burrows, CEO of Oxford BioDynamics , commented:
"Having someone of Steve's calibre in the OBD commercial team is
a real endorsement of our technology and its potential. He has a
wealth of experience in this industry and the ideal skill set to
drive our commercial efforts with PSE. His leadership and knowledge
will be invaluable across all areas of our growing product
portfolio."
"While it is currently early days for the PSE test in the
market, the signs are promising. We have work to do so establish
ourselves fully in the testing market, but appointments of this
quality are crucial in strengthening and furthering our progress
towards that goal."
-Ends-
For further details please contact:
Oxford BioDynamics Plc
Jon Burrows, CEO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Nominated Adviser and Broker
Stephane Auton
Iain Sexton +44 (0)20 7408 4090
Instinctif Partners +44 (0)20 7457 2020
Melanie Toyne-Sewell OxfordBioDynamics@instinctif.com
Rozi Morris
Jack Kincade
Notes to Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
Its flagship products are the EpiSwitch(R) CiRT (Checkpoint
Inhibitor Response Test) and EpiSwitch(R) PSE (EpiSwitch Prostate
Screening test) blood tests. CiRT is a predictive immune response
profile for immuno-oncology (IO) checkpoint inhibitor treatments,
launched in February 2022. PSE is a blood test that boosts the
predictive accuracy of a PSA test from 55% to 94% when testing the
presence or absence of prostate cancer, which has been launched in
the US and UK in September 2023.
In March 2021, the Company launched its first commercial
prognostic test, EpiSwitch(R) CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker discovery, EpiSwitch(R) Explorer
Array Kit, which is available for purchase by the life science
research community.
The Company's product portfolio is based on a proprietary 3D
genomic biomarker platform, EpiSwitch(R), which can build molecular
diagnostic classifiers for the prediction of response to therapy,
patient prognosis, disease diagnosis and subtyping, and residual
disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 15,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial office in
Gaithersburg and a clinical laboratory in Frederick, MD, USA, and a
reference laboratory in Penang, Malaysia.
For more information, please visit the Company's website,
www.oxfordbiodynamics.com, or follow OBD on Twitter
(@OxBioDynamics) and LinkedIn.
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 15,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcomes, EpiSwitch(R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFSTLFLDIIV
(END) Dow Jones Newswires
November 08, 2023 02:00 ET (07:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024